Nivolumab in combination with R-CHOP for treatment-naïve diffuse large B-cell lymphoma: an evaluation of safety and efficacy

Abstract: Approximately 20% of diffuse large B-cell lymphoma have aberrations involving the programmed death ligands 1 and 2 (PD-L1/PD-L2) locus. This justifies the investigation of PD-1 checkpoint inhibitors in the frontline therapy setting in a bid to improve outcomes, especially in patients with...

Fuld beskrivelse

Bibliografiske detaljer

Principais autores:	Oluwatobi Odetola, Shuo Ma, Jane Winter, Barbara Pro, Ishan Roy, Ping Xie, Bin Zhang, Qing Chen, George P. Koulogeorgas, Xinlei Mi, Ruohui Chen, Yangruijue Ma, Xiaodan Tang, Robert Bayer, Robert Eisner, Valerie Nelson, Habib Shaikh, Dean Tsarwhas, Faisal Saghir, Parameswaran Venugopal, Leo I. Gordon, Reem Karmali
Format:	Artigo
Sprog:	Inglês
Udgivet:	Elsevier 2025-11-01
Serier:	Blood Advances
Online adgang:	http://www.sciencedirect.com/science/article/pii/S2473952925004355
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!